AEZS-150 (Delayed Clearance Parathyroid Hormone Fusion Polypeptides DC-PTH)
Treatment of Chronic Hypoparathyroidism
AEZS-150 (DC-PTH) is the active part of the parathyroid hormone, PTH1-34, linked to a modified version of the growth hormone binding protein (GHBP) with the goal of replacing the PTH activity for one week.
We envision self-administered weekly injections of AEZS-150 to maintain normal serum calcium, phosphate levels, and urinary calcium secretion in patients with hypoparathyroidism.
Progressive metabolic disorder resulting from insufficient secretion of parathyroid hormone
Leads to chronic deficiency of calcium in the blood affecting a number of systems including the neuromuscular and cardiovascular
Last endocrine disorder where hormone replacement is not standard of care
Market opportunity: US: 60,000 and Europe: 70,000¹
Expected to be $2.7 billion market by 2028¹
1. DelveInsight 2022 Hypoparathyroidism – Market insight, epidemiology, and market forecast – 2032
Demonstrated Preclinical Efficacy In Vivo
Cinacalcet administration rapidly induces classical symptoms of hypoparathyroidism, i.e. reduced plasma calcium level for up to 12-24 h
Single treatment with 20 nmol/kg DC-PTH (AEZS-150) at t0h normalizes calcium level at 12 h, effect correlates with plasma exposure
Six subsequent treatments of 20 nmol/kg PTH 1-34 (t0-5h) provide only limited improvement of calcium levels
The plasma DC-PTH level reaches a maximum after 12 h and demonstrates delayed clearance